title: Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.
abstract: The development of a preventative HIV/AIDS vaccine is challenging due to the diversity of viral genome sequences, especially in the viral envelope (Env₁₆₀). Since it is not possible to directly match the vaccine strain to the vast number of circulating HIV-1 strains, it is necessary to develop an HIV-1 vaccine that can protect against a heterologous viral challenge. Previous studies from our group demonstrated that a mixture of wild type clade B Env(gp160s) were able to protect against a heterologous clade B challenge more effectively than a consensus clade B Envg(p160) vaccine. In order to broaden the immune response to other clades of HIV, in this study rhesus macaques were vaccinated with a polyvalent mixture of purified HIV-1 trimerized consensus Envg(p140) proteins representing clades A, B, C, and E. The elicited immune responses were compared to a single consensus Env(gp140) representing all isolates in group M (Con M). Both vaccines elicited anti- Env(gp140) IgG antibodies that bound an equal number of HIV-1 Env(gp160) proteins representing clades A, B and C. In addition, both vaccines elicited antibodies that neutralized the HIV-1(SF162) isolate. However, the vaccinated monkeys were not protected against SHIV(SF162p4) challenge. These results indicate that consensus Env(gp160) vaccines, administered as purified Env(gp140) trimers, elicit antibodies that bind to Env(gp160s) from strains representing multiple clades of HIV-1, but these vaccines did not protect against heterologous SHIV challenge.
authors.affiliation: Center for Vaccine Research, University of Pittsburgh, 9047 BST3, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA.
authors.forename: Hermancia S
authors.initials: HS
authors.lastname: Eugene
authors.forename: Brooke R
authors.initials: BR
authors.lastname: Pierce-Paul
authors.forename: Jodi K
authors.initials: JK
authors.lastname: Cragio
authors.forename: Ted M
authors.initials: TM
authors.lastname: Ross
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008253:Macaca mulatta; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D054299:env Gene Products, Human Immunodeficiency Virus / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D007074:Immunoglobulin G; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1
references.citation: Curr HIV Res. 2010 Dec;8(8):613-21
references.pmid: 21054255
references.citation: Virology. 2007 Mar 30;360(1):218-34
references.pmid: 17097711
references.citation: J Antimicrob Chemother. 2003 Feb;51(2):229-40
references.pmid: 12562686
references.citation: AIDS Res Hum Retroviruses. 2012 Sep;28(9):1063-72
references.pmid: 22214267
references.citation: Nature. 2012 Jan 04;482(7383):89-93
references.pmid: 22217938
references.citation: Virology. 2004 Oct 1;327(2):262-72
references.pmid: 15351214
references.citation: J Exp Med. 2010 Aug 30;207(9):2003-17
references.pmid: 20679401
references.citation: Curr HIV Res. 2010 Dec;8(8):622-9
references.pmid: 21054250
references.citation: Vaccine. 2009 Jul 9;27(32):4337-49
references.pmid: 19389453
references.citation: Vaccine. 2011 Aug 5;29(34):5611-22
references.pmid: 21693155
references.citation: Science. 2002 Jun 28;296(5577):2354-60
references.pmid: 12089434
references.citation: J Virol. 2012 Jan;86(1):277-83
references.pmid: 22031937
references.citation: Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11440-5
references.pmid: 21709254
references.citation: J Virol. 2010 Oct;84(19):10354-65
references.pmid: 20668079
references.citation: Nat Rev Immunol. 2002 Sep;2(9):706-13
references.pmid: 12209139
references.citation: J Virol. 2008 Jun;82(11):5618-30
references.pmid: 18367534
references.citation: Vaccine. 2008 Feb 20;26(8):1098-110
references.pmid: 18243434
references.citation: PLoS One. 2011 Mar 31;6(3):e18207
references.pmid: 21483815
references.citation: Vaccine. 2006 Jun 29;24(26):5442-51
references.pmid: 16621193
references.citation: J Infect Dis. 2006 Oct 1;194(7):904-11
references.pmid: 16960777
references.citation: Trends Mol Med. 2012 Mar;18(3):182-92
references.pmid: 22240486
references.citation: Vaccine. 2010 Oct 8;28(43):7016-24
references.pmid: 20728522
references.citation: N Engl J Med. 2012 Apr 5;366(14):1275-86
references.pmid: 22475592
references.citation: Protein Eng Des Sel. 2004 Oct;17(10):749-58
references.pmid: 15542540
references.citation: J Virol. 2010 Feb;84(3):1302-13
references.pmid: 19906907
references.citation: Immunol Lett. 2010 Mar 10;129(1):32-8
references.pmid: 20064559
references.citation: N Engl J Med. 2009 Dec 3;361(23):2209-20
references.pmid: 19843557
references.citation: Virology. 2006 Sep 1;352(2):438-49
references.pmid: 16780913
references.citation: Curr HIV Res. 2007 Nov;5(6):572-7
references.pmid: 18045113
references.citation: J Virol. 2007 Aug;81(16):8827-32
references.pmid: 17537848
references.citation: PLoS One. 2011;6(7):e22010
references.pmid: 21799765
references.citation: Viruses. 2009 Dec;1(3):1265-94
references.pmid: 21994593
references.citation: Science. 2001 Aug 10;293(5532):1155-9
references.pmid: 11498595
references.citation: Curr HIV/AIDS Rep. 2012 Mar;9(1):5-15
references.pmid: 22249405
references.citation: Expert Rev Vaccines. 2008 Nov;7(9):1405-17
references.pmid: 18980542
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10489-94
references.pmid: 18650391
references.citation: Adv Exp Med Biol. 2006;586:249-64
references.pmid: 16893077
references.citation: Vaccine. 2011 Apr 5;29(16):2918-32
references.pmid: 21338681
references.citation: AIDS. 2008 Jan 30;22(3):339-48
references.pmid: 18195560
references.citation: J Virol. 2005 Oct;79(19):12311-20
references.pmid: 16160158
references.citation: J Virol. 2010 Jun;84(12):5975-85
references.pmid: 20392857
references.citation: Vaccine. 2008 Jan 30;26(5):727-37
references.pmid: 18096278
references.citation: Virology. 2006 Aug 15;352(1):131-44
references.pmid: 21894641
references.citation: Virology. 2006 Sep 30;353(2):268-82
references.pmid: 17039602
references.citation: Mol Ther. 2007 Feb;15(2):411-21
references.pmid: 17235321